2026年8月4日，科济药业控股有限公司（股票代码：02171）公告，其自主研发的靶向BCMA通用型CAR-T细胞产品CT0596已获得国家药品监督管理局的临床试验申请（IND）批准，用于治疗复发╱难治的多发性骨髓瘤（R/R MM）患者。
CT0596基于公司THANK-u Plus™平台开发，当前已在R/R MM或浆细胞白血病（PCL）适应症中开展研究者发起的临床试验（IIT）。相关研究结果已于2026年欧洲血液学协会年会上以壁报形式展示，显示出初步良好的安全性及疗效信号。
公司表示，未来还计划在其他浆细胞肿瘤及自身反应性浆细胞驱动的自身免疫性疾病中进一步评估CT0596。
科济药业为一家专注创新CAR-T细胞疗法的生物制药企业，已构建涵盖靶点发现、临床前研究、临床开发及商业化生产的端到端能力。公司强调，无法确保CT0596最终能够成功开发或商业化，提醒投资者在买卖公司股票时保持审慎。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.